First Gene Therapy For Heart Failure Offered In Clinical Trials
NewYork-Presbyterian Hospital/Columbia University Medical Center is the only center in the New York City area where the therapy is currently available.
Patients enrolled in the multicenter CUPID trial (Calcium Up-Regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease) will undergo a minimally invasive cardiac catheterization procedure that will introduce a specially engineered gene that stimulates production of an enzyme necessary for the heart to pump more efficiently.
"This new therapy seeks to replenish the levels of this enzyme by introducing the gene for SERCA2a, which is depressed in these patients. If proven effective, this approach could be an alternative to heart transplant for patients without any other options," says Dr. Donna Mancini, the study's principal investigator at NewYork-Presbyterian Hospital/Columbia University Medical Center, where she is medical director of cardiac transplantation. She also is professor of medicine at Columbia......
View the rest of this paper...
Approximate Word Count: 354
Approximate Pages: 2 (250 words per double-spaced page)
Why should you join Frat Files?
- - It's safe, secure, and private.
- - Instant access to over 100,000 papers. New papers are added hourly.
- - Fast and reliable customer support.
Similar Essays
-
First Gene Therapy For Heart Failure Offered In Clinical Trials
First Gene Therapy For Heart Failure Offered In Clinical Trials.
NewYork-Presbyterian Hospital/Columbia University Medical Center ... -
Biogen Analysis
... expertise to accelerate the explication of gene function ... First, the study's primary
endpoint measures only relapses, rather ... since the main goal of therapy in MS ...
Frat Files
Members
Information
